U.S. Non-insulin Therapies for Diabetes Market 2022-2030 Emerging News

The Global Non-insulin Therapies for Diabetes Market Report is a compilation of comprehensive research studies of various aspects of the Non-insulin Therapies for Diabetes Market. With accurate data and highly authentic information, a brilliant attempt is made to paint a true, transparent picture of the current and future situations of the global Non-insulin Therapies for Diabetes market. Market participants can use this powerful tool when creating effective business plans or making major changes to their strategies. The report discusses the growth of the global as well as regional markets. It also throws light on high-growth segments of the global Non-insulin Therapies for Diabetes market and how they will evolve in the years to come.

Read Detailed Index of full Research Study @ https://www.absolutemarketsinsights.com/reports/Global-Non-insulin-Therapies-for-Diabetes-Market-2019-2027-259

Global non-insulin therapies for diabetes market was valued at US$ 61,090.1 million in 2022 and is estimated to reach US$ 105,461.5 million by 2030, growing at a CAGR of 6.3% over the forecast period.. Eli Lilly and Company, Eurofarma Laboratorios S.A., GlaxoSmithKline plc, Merck Sharp & Dohme Corp. (subsidiary of Merck & Co., Inc), Novo Nordisk, Luye Pharma Group, and Pfizer Inc. among others.

Increasing demand for combination therapy and rapid advancements in diabetes treatment are fueling the global non-insulin therapies for diabetes market growth. Combination therapies such as administration of anti-hyperglycemic drugs alone or in combination with insulin used for the treatment of type 2 diabetes. Moreover, from the demand side, surge in people suffering from type 2 diabetes happens to be the primary reason behind growing adoption of various non-insulin therapies across the globe.

As per International Diabetes Foundation (IDF), in 2017, the global prevalence of diabetic patients stood at 425 million, of which 400 million were suffering from type 2 diabetes. Moreover, according to the World Health Organization (WHO), in 2017, diabetes was among top three cause of death with more than 30 million cases in the U.S. alone.

Technological advancements expected to be key growth enabler in the non-insulin therapies for diabetes market. Key vendors operating in the market developed technology platforms such as protein oral delivery (POD) technology (Oramed Pharmaceuticals), Eligen (Emisphere Technologies), Axcess (Diabetology), and PharmFilm Technology (MonoSol Rx) for oral administration of GLP-1 agonists. Moreover, companies such as Panacea and ScinoPharm are in the early stage development of oral capsules for the DPP4 inhibitors. 

However, patent expiries of the currently available drugs, and the potential health hazards associated with the use of these inhibitors proves to be major hurdle in market expansion path.

Thiazolidinediones, Insulin secretagogues, alpha-glucosidase inhibitors (AGIs), Sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, Glinides/Meglitinides, Amylin agonists, Metformin, Glucagon like peptide-1 (GLP-1) agonists, and Biguanides are some of the products used in the non-insulin therapies for diabetes market. Oral product segment held the largest market share in 2018 and it is estimated to expand at a rapid rate over the projection period. The growth is attributed to the presence of more oral drugs in the market.

North America non-insulin therapies for diabetes market, held largest market share and is estimated to hold its dominance in years to come. As per the International Diabetes Foundation (IDF), in the U.S. alone approximately, 17,100 new cases of diabetes were reported. This high incidence rate is driving the market growth in the concerned region.

Asia Pacific non-insulin therapies for diabetes market is the most lucrative, owing to surge in diabetes burden in India and China. Both countries collectively has more than 180 million people suffering from diabetes. Moreover, according to the American Diabetes Association (ADA), incidence rate of type 2 diabetes in South East Asia is expected to be more than 150%, by 2035.

The report provides both, qualitative and quantitative research of global non-insulin therapies for diabetes market, it also provides penetrative insights into the rational scenario and favored development methods adopted by key contenders. The report also offers extensive research on the key players in the market and detailed insights into the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by major players are also recognized and analyzed in the report. For each company, the report recognizes its headquarter, competitors, product/service type, application and specification, pricing, and gross margin.

Global Non-Insulin Therapies For Diabetes Market:

  • By Product
    • Oral
      • Thiazolidinediones (TZDs)
      • Insulin secretagogues
      • Alpha-glucosidase inhibitors (AGIs)
      • Sulfonylureas
      • Dipeptidyl peptidase-4 (DPP-4) inhibitors
      • Sodium-glucose cotransporter-2 (SGLT2) inhibitors
      • Glinides/Meglitinides
      • Metformin
      • Biguanides
      • Others
    • Injectable
      • Glucagon-like peptide-1 (GLP-1) agonists
      • Amylin Agonists
      • Others
  • By Distributor
    • Hospital Pharmacy
    • Retail Pharmacies
    • Online Pharmacy
    • Others
  • By Geography
    • North America
      • U.S.
      • Canada
      • Mexico
      • Rest of North America
    • Asia Pacific
      • China
      • Japan
      • India
      • New Zealand
      • Australia
      • South Korea
      • Southeast Asia
        • Indonesia
        • Thailand
        • Malaysia
        • Singapore
        • Rest of Southeast Asia
      • Rest of Asia Pacific
    • Europe
      • France
      • The UK
      • Spain
      • Germany
      • Italy
      • Nordic Countries
        • Denmark
        • Finland
        • Iceland
        • Sweden
        • Norway
      • Benelux Union
        • Belgium
        • The Netherlands
        • Luxembourg
      • Rest of Europe
    • Middle East and Africa
      • Saudi Arabia
      • UAE
      • Egypt
      • Kuwait
      • South Africa
      • Rest of Middle East & Africa
    • Latin America
      • Argentina
      • Brazil
      • Rest of Latin America

Besides target market information, Absolute Markets Insights also provides information about your competitor, your customers, products etc. A few techniques we use are:

  1. Customer analysis
  2. Competitor analysis
  3. Risk analysis
  4. Product research
  5. Advertising research
  6. E-mail survey and many more…
  7. Market Research Methodology

We define the research problem: The step defining the research problem exists of two main steps:

  1. Formulating the problem
  2. Establishing research objectives
  3. Selecting and Establishing Research Design

The step selecting and establishing research design consists of three main steps:

  1. Select the research design
  2. Identify information types and sources
  3. Determine and design research instrument

About Us:

Absolute Markets Insights assists in providing accurate and latest trends related to consumer demand, consumer behavior, sales, and growth opportunities, for the better understanding of the market, thus helping in product designing, featuring, and demanding forecasts. Our experts provide you the end-products that can provide transparency, actionable data, cross-channel deployment program, performance, accurate testing capabilities and the ability to promote ongoing optimization. From the in-depth analysis and segregation, we serve our clients to fulfill their immediate as well as ongoing research requirements. Minute analysis impact large decisions and thereby the source of business intelligence (BI) plays an important role, which keeps us upgraded with current and upcoming market scenarios.

Contact Us:

Contact Name: Shreyas Tanna

Company: Absolute Markets Insights

Email Id: sales@absolutemarketsinsights.com

Phone: IN +91-7400-24-24-24, US +1-510-420-1213

Website: www.absolutemarketsinsights.com

Leave a Reply

Your email address will not be published. Required fields are marked *